华纳药厂：拟购买、出售资产

Group 1 - The core strategy of the company is to advance the "combination of generic and innovative drugs" by focusing on "intensive consolidation of generics" and "spot breakthroughs in innovative drugs" to enhance its core competitiveness [1] - The subsidiary, Qianlie Pharmaceutical, is focused on the ophthalmic medication sector, continuously optimizing its product layout and developing promising ophthalmic drugs [1] - The company plans to optimize its formulation product pipeline through the integration with Qianlie Pharmaceutical, aligning with its strategic planning and industrial positioning [1] Group 2 - The company intends to purchase five formulation projects from Qianlie Pharmaceutical, including injection products such as Indocyanine Green and Sodium Fluorescein, for a total consideration of 10.1 million yuan, funded by its own resources [1] - The company also plans to sell four formulation projects, including Diquafosol Sodium Eye Drops, to Qianlie Pharmaceutical for a total consideration of 7 million yuan [1]